FrancophonIA/ELRC3.0 huggingface dataset:
English: Push the needle into the vial of Insulatard, turn the vial and syringe upside down and draw out the dose you have been prescribed.
Estonian: Lükake nõel Insulatard'i viaali sisse, pöörake viaalil (koos süstlaga) põhi ülespoole ja tõmmake süstlasse õige annus.
English: Combination of Insulatard with pioglitazone
Estonian: Insulatard'i ja pioglitasooni kombinatsioon
English: Read carefully the Instructions on how to use Insulatard FlexPen included in this package leaflet.
Estonian: Lugege hoolikalt pakendi infolehes sisalduvat Insulatard FlexPen'i kasutusjuhendit.
English: ► Needles and Insulatard FlexPen must not be shared.
Estonian: ► Nõelu ja Insulatard FlexPen'i ei tohi anda kasutamiseks teistele.
English: Insulatard is often given in combination with fast-acting insulin preparations.
Estonian: Insulatard'i määratakse sageli kombinatsioonis lühikese toimeajaga insuliinidega.
English: A number of cleavage (hydrolysis) sites on the human insulin molecule have been proposed; none of the metabolites formed following the cleavage are active.
Estonian: Lõhustumisjärgselt moodustuvatest metaboliitidest ei ole ükski aktiivne.
English: How to store Insulatard
Estonian: Kuidas süstida Insulatard'i
English: Insulatard FlexPen is only suitable for subcutaneous injections.
Estonian: Insulatard FlexPen on ette nähtud üksnes subkutaanseks süstimiseks.
English: EU/1/02/233/005 1 cartridge of 3 ml EU/1/02/233/006 5 cartridges of 3 ml EU/1/02/233/007 10 cartridges of 3 ml
Estonian: EU/1/02/233/005 1 kolbampull x 3 ml EU/1/02/233/006 5 kolbampulli x 3 ml EU/1/02/233/007 10 kolbampulli x 3 ml
English: ► Insulatard Penfill is only suitable for injecting under the skin using a reusable pen.
Estonian: ► Insulatard Penfill on ette nähtud üksnes nahaaluseks süstimiseks korduvkasutatava süstevahendiga.
English: ► Insulatard FlexPen is only suitable for injecting under the skin.
Estonian: ► Insulatard FlexPen on ette nähtud üksnes nahaaluseks süstimiseks.
English: Insulatard FlexPen 100 international units/ml suspension for injection in pre-filled pen.
Estonian: Insulatard FlexPen, 100 rahvusvahelist ühikut/ml süstesuspensioon pen-süstlis.
English: EU/1/02/233/001 1 vial of 10 ml EU/1/02/233/002 5 vials of 10 ml
Estonian: EU/1/02/233/001 1 viaal x 10 ml EU/1/02/233/002 5 viaali x 10 ml
English: EU/1/02/233/003 1 vial of 10 ml EU/1/02/233/004 5 vials of 10 ml
Estonian: EU/1/02/233/003 1 viaal x 10 ml EU/1/02/233/004 5 viaali x 10 ml
English: ► Insulatard InnoLet is only suitable for injecting under the skin.
Estonian: ► Insulatard InnoLet on ette nähtud üksnes nahaaluseks süstimiseks.
English: Draw into the syringe the same amount of air as the dose of Insulatard.
Estonian: Tõmmake süstlasse õhku samas koguses vajamineva Insulatard'i annusega.
English: How to take Insulatard
Estonian: Kuidas kasutada Insulatard'i
English: EU/1/02/233/016 5 packs of 1 x 10 ml vial
Estonian: EU/1/02/233/016 5 pakki 1 x 10 ml viaali
English: EU/1/02/233/017 5 packs of 1 x 10 ml vial
Estonian: EU/1/02/233/017 5 pakki 1 x 10 ml viaali
English: EU/1/02/233/013 1 pen of 3 ml EU/1/02/233/014 5 pens of 3 ml EU/1/02/233/015 10 pens of 3 ml
Estonian: EU/1/02/233/013 1 pen-süstel x 3 ml EU/1/02/233/014 5 pen-süstlit x 3 ml EU/1/02/233/015 10 pen-süstlit x 3 ml
English: Insulatard InnoLet is a pre-filled pen designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm. InnoLet delivers 1-50 units in increments of 1 unit.
Estonian: Insulatard InnoLet on pen-süstel, mis on ette nähtud kasutamiseks koos kuni 8 mm pikkuste ühekordsete nõeltega NovoFine või NovoTwist.
English: Insulatard InnoLet 100 international units/ml suspension for injection in pre-filled pen.
Estonian: Insulatard InnoLet, 100 rahvusvahelist ühikut/ml süstesuspensioon pen-süstlis.
English: Insulatard 40 international units/ml suspension for injection in vial.
Estonian: Insulatard, 40 rahvusvahelist ühikut/ml süstesuspensioon viaalis.
English: EU/1/02/233/010 1 pen of 3 ml EU/1/02/233/011 5 pens of 3 ml EU/1/02/233/012 10 pens of 3 ml
Estonian: EU/1/02/233/010 1 pen-süstel x 3 ml EU/1/02/233/011 5 pen-süstlit x 3 ml EU/1/02/233/012 10 pen-süstlit x 3 ml
English: Insulatard InnoLet is only suitable for subcutaneous injections.
Estonian: Insulatard InnoLet on ette nähtud üksnes subkutaanseks süstimiseks.
English: Insulatard Penfill is only suitable for injecting under the skin using a reusable pen.
Estonian: Insulatard Penfill on ette nähtud üksnes subkutaanseks süstimiseks korduvkasutatava süstevahendiga.
English: Paediatric population Insulatard can be used in children and adolescents.
Estonian: Lapsed Lapsed ja noorukid võivad kasutada Insulatard'i.
English: Insulatard FlexPen is a pre-filled pen designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm. FlexPen delivers 1-60 units in increments of 1 unit.
Estonian: Insulatard FlexPen on pen-süstel, mis on ette nähtud kasutamiseks koos kuni 8 mm pikkuste ühekordsete nõeltega NovoFine või NovoTwist.
English: ► There are no restrictions on treatment with Insulatard during breast-feeding.
Estonian: ► Insulatard'i imetamisaegseks kasutamiseks ei ole piiranguid.
English: Insulatard Penfill 100 IU/ml Suspension for injection Insulin human SC
Estonian: Insulatard Penfill 100 RÜ/ml Süstesuspensioon Insulinum humanum s.c.
English: Insulatard Penfill 100 international units/ml suspension for injection in cartridge.
Estonian: Insulatard Penfill, 100 rahvusvahelist ühikut/ml süstesuspensioon kolbampullis.
English: Insulatard FlexPen is only suitable for injecting under the skin.
Estonian: Insulatard FlexPen on ette nähtud üksnes nahaaluseks süstimiseks.
English: Insulatard 100 international units/ml suspension for injection in vial.
Estonian: Insulatard, 100 rahvusvahelist ühikut/ml süstesuspensioon viaalis.
English: Package leaflet: Information for the user Insulatard 40 IU/ml (international units/ml) suspension for injection in vial human insulin
Estonian: Pakendi infoleht: teave kasutajale Insulatard, 40 RÜ/ml (rahvusvahelist ühikut/ml) süstesuspensioon viaalis
English: There is no restriction on treatment with Insulatard during breast-feeding.
Estonian: Imetamisperioodil piirangud raviks Insulatard'iga puuduvad.
English: Insulatard contains sodium
Estonian: Insulatard sisaldab naatriumi
English: Package leaflet: Information for the user Insulatard FlexPen 100 IU/ml (international units/ml) suspension for injection in pre-filled pen human insulin
Estonian: Pakendi infoleht: teave kasutajale Insulatard FlexPen, 100 RÜ/ml (rahvusvahelist ühikut/ml) süstesuspensioon pen-süstlis
English: Insulatard 40 IU/ml Suspension for injection Insulin human SC
Estonian: Insulatard 40 RÜ/ml Süstesuspensioon Insulinum humanum s.c.
English: Package leaflet: Information for the user Insulatard InnoLet 100 IU/ml (international units/ml) suspension for injection in pre-filled pen human insulin
Estonian: Pakendi infoleht: teave kasutajale Insulatard InnoLet, 100 RÜ/ml (rahvusvahelist ühikut/ml) süstesuspensioon pen-süstlis
English: Package leaflet: Information for the user Insulatard 100 IU/ml (international units/ml) suspension for injection in vial human insulin
Estonian: Pakendi infoleht: teave kasutajale Insulatard, 100 RÜ/ml (rahvusvahelist ühikut/ml) süstesuspensioon viaalis
English: Insulatard FlexPen 100 IU/ml Suspension for injection in pre-filled pen Insulin human
Estonian: Insulatard FlexPen 100 RÜ/ml Süstesuspensioon pen-süstlis Insulinum humanum
English: Insulatard Penfill Administration with an insulin delivery system
Estonian: Manustamine insuliini süstevahendiga
English: Package leaflet: Information for the user Insulatard Penfill 100 IU/ml (international units/ml) suspension for injection in cartridge human insulin
Estonian: Pakendi infoleht: teave kasutajale Insulatard Penfill, 100 RÜ/ml (rahvusvahelist ühikut/ml) süstesuspensioon kolbampullis
English: Insulatard FlexPen 100 IU/ml Suspension for injection Insulin human
Estonian: Insulatard FlexPen 100 RÜ/ml Süstesuspensioon Insulinum humanum s.c.
English: Insulatard InnoLet 100 IU/ml Suspension for injection in pre-filled pen Insulin human
Estonian: Insulatard InnoLet 100 RÜ/ml Süstesuspensioon pen-süstlis Insulinum humanum
English: Insulatard 100 IU/ml Suspension for injection Insulin human SC
Estonian: Insulatard 100 RÜ/ml Süstesuspensioon Insulinum humanum s.c.
English: Insulatard InnoLet 100 IU/ml Suspension for injection Insulin human
Estonian: Insulatard InnoLet 100 RÜ/ml Süstesuspensioon Insulinum humanum s.c.
English: Insulatard InnoLet is only suitable for injecting under the skin.
Estonian: Insulatard InnoLet on ette nähtud üksnes nahaaluseks süstimiseks.
English: Insulatard 40 IU/ml Suspension for injection Insulin human
Estonian: Insulatard 40 RÜ/ml Süstesuspensioon Insulinum humanum
English: Insulatard Penfill 100 IU/ml Suspension for injection in cartridge Insulin human
Estonian: Insulatard Penfill 100 RÜ/ml Süstesuspensioon kolbampullis Insulinum humanum
English: 1 vial contains 10 ml equivalent to 1,000 international units.
Estonian: Insulatard viaal (100 rahvusvahelist ühikut/ml) 1 viaal sisaldab 10 ml, mis vastab 1000 rahvusvahelisele ühikule.
English: Insulatard 100 IU/ml Suspension for injection Insulin human
Estonian: Insulatard 100 RÜ/ml Süstesuspensioon Insulinum humanum
English: 1 vial contains 10 ml equivalent to 400 international units.
Estonian: Insulatard viaal (40 rahvusvahelist ühikut/ml) 1 viaal sisaldab 10 ml, mis vastab 400 rahvusvahelisele ühikule.
English: Preparing your Insulatard FlexPen
Estonian: Insulatard FlexPen'i ettevalmistamine
English: Aprotinin
Estonian: Aprotiniin
English: All risks should be captured in the risk management plan.
Estonian: Kõik riskid peavad olema hõlmatud riskijuhtimiskavaga.
English: Divergent positions are appended to the Opinion.
Estonian: Lahknevad seisukohad on lisatud arvamusele.
English: In addition, results from observational studies are conflicting.
Estonian: Samuti on vaatlusuuringute tulemused vastuolulised.
English: In this regard, a study on the profile of aprotinin use is needed, particularly in light of the importance of adequate anticoagulation.
Estonian: Selles osas on vaja aprotiniini kasutamisprofiili uuringut, eriti arvestades piisava antikoagulatsiooni tähtsust.
English: This document presents the conclusions on aprotinin.
Estonian: Selles dokumendis esitatakse järeldused aprotiniini kohta.
English: All risks of aprotinin known to date were considered.
Estonian: Arutati aprotiniini kõiki seni teadaolevaid riske.
English: Sufficient evidence of efficacy in this patient population is available.
Estonian: Selles patsiendipopulatsioonis on olemas piisavad andmed efektiivsuse kohta.
English: Aprotinin should only be used after careful consideration of the benefits and risks, and the consideration that alternative treatments are available (see section 4.4 and 5.1).
Estonian: Aprotiniini tohib kasutada alles pärast kasulikkuse ja riskide ning teiste olemasolevate alternatiivsete ravimeetodite hoolikat kaalumist (vt lõigud 4.4 ja 5.1).
English: The conditions with regard to the safe and effective use of the medicinal product to be implemented by the member states are set out in annex IV of the opinion.
Estonian: Liikmesriikides kohaldatavad ravimite ohutu ja efektiivse kasutamise tingimused on komitee arvamuse IV lisas.
English: The observational studies have provided conflicting results related to mortality as discussed above.
Estonian: Vaatlusuuringud on seoses suremusega pakkunud vasturääkivaid tulemusi, nagu eespool mainitud.
English: The CHMP noted the uncertainties and advised that the interpretation of all available data from observational studies is limited.
Estonian: Inimravimite komitee võttis ebaselgused teadmiseks ja leidis, et vaatlusuuringute kõikide olemasolevate andmete tõlgendamine on piiratud.
English: Overall summary of the scientific evaluation of referral on antifibrinolytics Aprotinin containing medicinal products (see Annex I)
Estonian: Antifibrinolüütilise toimega ravimite esildise teadusliku hindamise üldkokkuvõte Aprotiniini sisaldavad ravimid (vt I lisa)
English: A CHMP scientific advisory group (SAG) meeting was held in October 2011 and its views were considered by the CHMP in the framework of this review.
Estonian: Oktoobris 2011 toimus inimravimite komitee teadusnõuanderühma koosolek, mille seisukohti võttis inimravimite komitee käesoleva läbivaatamise raames ka arvesse.
English: In addition, aprotinin should be used only in adult patients (data in children are not available) who are at ‘high-risk' of major blood loss.
Estonian: Lisaks tohib aprotiniini kasutada ainult täiskasvanud patsientidel (laste andmed puuduvad), kellel esineb suure verekaotuse suur risk.
English: Special attention is also to be given to patients with renal impairment and to the possible occurrence anaphylactic reactions.
Estonian: Erilist tähelepanu tuleb pöörata ka neerukahjustusega patsientidele ja võimalikele anafülaktilistele reaktsioonidele.
English: The quality review of documents templates were taken into account during this review.
Estonian: Läbivaatamisel võeti arvesse ka dokumendivormide kvaliteedikontrolli.
English: In March 2010 Germany triggered an article 31 referral to assess the benefits and risks of the antifibrinolytic drugs aprotinin, EACA and TXA in all their approved indications.
Estonian: 2010. aasta märtsis algatas Saksamaa artikli 31 kohase esildise antifibrinolüütilise toimega ravimite aprotiniini, aminokaproonhappe ning traneksaamhappe kasulikkuse ja riskide hindamiseks kõikide heakskiidetud näidustuste korral.
English: These concerns echoed those of a few published observational studies.
Estonian: Need küsimused sarnanesid mõnes varem avaldatud vaatlusuuringus tõstatatud küsimustele.
English: In the initial review in 2007 concerns had also been raised by the findings of three observational studies.
Estonian: Esmase menetluse käigus 2007. aastal tõstatati küsimused ka kolme vaatlusuuringu alusel.
English: Re-surgery due to bleeding carries high risk for increased morbidity which also was emphasised by the group of external experts consulted by the CHMP.
Estonian: Verejooksu tõttu toimuva kordusoperatsiooniga kaasneb suurema haigestumuse suur risk, mida rõhutas ka inimravimite komiteele nõu andnud välisekspertide rühm.
English: The MAHs will submit a revised protocol for the registry to national competent authorities.
Estonian: Müügilubade hoidjad esitavad patsiendiregistri läbivaadatud aruande pädevatele riiklikele asutustele.
English: There are no indications that the efficacy would vary by age or that the safety pattern of aprotinin would be different in elderly patients as compared to the overall study populations.
Estonian: Puuduvad andmed, et efektiivsus eri vanuses patsientidel oleks erinev või aprotiniini ohutusandmed eakatel patsientidel erineks üldiste uuringupopulatsioonide ohutusandmetest.
English: In case of repeated treatment, physicians should be aware of the risk, and manage their patients adequately.
Estonian: Kordusravi korral peavad arstid seda riski teadma ja arvestama patsientide ravis.
English: The final results of BART study have since become available, together with important new analysis of the study data.
Estonian: Uuringu BART lõplikud tulemused koos uuringuandmete uue olulise analüüsiga on nüüd olemas.
English: The deficiencies included the unexplained exclusion of patients from analysis, underlying differences in baseline characteristics between the study groups which were not homogenous in spite of randomisation, and the apparent reduced level of heparinisation in the aprotinin arm which would increase the risk of thrombogenic events in this group.
Estonian: Puudused olid patsientide põhjendamatu analüüsist väljajätmine, lähteomaduste erinevused uuringurühmades, mis ei olnud randomiseerimisele vaatamata homogeensed, ning näiliselt väiksem hepariniseeritus aprotiniinirühmas, mis suurendanuks rühmas trombootiliste juhtude riski.
English: Taking into account all the data available on the efficacy and safety of aprotinin to date, the CHMP considered that there is clear evidence of a patient population in which the efficacy of systemic aprotinin clearly outweighs its risks.
Estonian: Võttes arvesse kogu seni olemasolevat aprotiniini ohutus- ja efektiivsusteavet, järeldas inimravimite komitee, et on olemas selged andmed patsiendipopulatsiooni kohta, kellel on süsteemse aprotiniini efektiivsus selgelt suurem kui sellega kaasnevad riskid.
English: • The Committee considered that the product information should be updated to ensure that the information to healthcare professionals and patients is up-to-date.
Estonian: • Inimravimite komitee leidis, et ravimiteavet tuleb uuendada, et tervishoiutöötajad ja patsiendid saaksid ajakohast teavet.
English: The CHMP considered that all of these risks, along with the uncertainties on the findings from clinical trials and observational studies on mortality, should be appropriately reflected through warnings and recommendations in the product information and captured in the risk management plan.
Estonian: Inimravimite komitee leidis, et kõik need riskid - ning peale nende kliiniliste uuringute tulemuste ja vaatlusuuringute suremusandmete ebamäärasus - peavad olema ravimiteabes adekvaatselt kajastatud hoiatuste ja soovitustena ning hõlmatud riskijuhtimiskavaga.
English: The new data available to date however showed that the indication, and other sections of the product information, merited change, to take due account of known risks and the uncertainties associated with such risks.
Estonian: Uued andmed näitasid siiski, et näidustust ja teisi ravimiteabe osi tuleb muuta, et arvestada teadolevaid riske ja nendega seotud ebaselgusi.
English: Several data sources informed the opinion of the Committee, including available data from clinical studies, published literature, spontaneous reports and other data submitted by marketing authorisation holders (MAHs) of medicinal products containing aprotinin, EACA or TXA.
Estonian: Komitee arvamust toetasid mitmed andmeallikad, sh kliiniliste uuringute, spontaansete teadete ja avaldatud kirjanduse olemasolevad andmed ning muud aprotiniini, aminokaproonhapet või traneksaamhapet sisaldavate ravimite müügilubade hoidjate esitatud andmed.
English: These new data have now made it possible to identify the major flaws of the BART study, not identifiable before.
Estonian: Uued andmed on praegu võimaldanud tuvastada uuringu BART varem avastamata olulisi puudusi.
English: The marketing authorisations for aprotinin were suspended following the preliminary results of the BART study in 2007, and concerns raised over some observational studies.
Estonian: Aprotiniini müügiload peatati pärast 2007. aastal avaldatud uuringu BART esmaseid tulemusi, kui tõstatati küsimused mõne vaatlusuuringu suhtes.
English: The results of re-analysis of two of these studies did not show a statistically significant association between aprotinin treatment and myocardial infarction, and other cardiovascular endpoints; methodological questions were raised over a third observational study where a supplementary analysis also did not show a significant association between aprotinin and seven-day in-hospital mortality.
Estonian: Neist kahe uuringu kordusanalüüsi tulemused ei näidanud aprotiniinravi ja müokardiinfarkti ning muude kardiovaskulaarsete tulemusnäitajate statistiliselt olulist seost; tõstatati metodoloogilised küsimused kolmanda vaatlusuuringu suhtes, mille lisaanalüüs ei näidanud samuti aprotiniini ja 7-päevase haiglasuremuse olulist seost.
English: The marketing authorisations for aprotinin were suspended when concerns over its safety were raised in a previous review in 2007.
Estonian: Aprotiniini müügiload peatati, kui varasema, 2007. aasta menetluses tõstatati ravimi ohutuse küsimus.
English: Therefore the CHMP concluded that the balance of risks and benefits for aprotinin is positive under normal conditions of use subject to the revision of the indication as follows:
Estonian: Seetõttu järeldas inimravimite komitee, et aprotiniini riski ja kasulikkuse suhe on normaalsete kasutustingimuste korral positiivne järgmisel läbivaadatud näidustusel:
English: As a result, the Committee agreed on the lifting of the suspension for aprotinin with the balance of risks and benefits considered positive in the following revised indication for aprotinin:
Estonian: Selle tulemusena nõustus komitee, et aprotiniini kasutamise peatamine tuleb lõpetada, ja leidis, et aprotiniini kasulikkuse ja riski suhe on positiivne järgmisel läbivaadatud näidustusel:
English: The scientific conclusions and the grounds for the lifting of the suspension and amendment of the marketing authorisation are set out in annex II of the opinion.
Estonian: Teaduslikud järeldused ning müügilubade peatamise lõpetamise ja müügilubade muutmise alused on komitee arvamuse II lisas.
English: • The Committee considered all data provided by the MAHs in writing and at the oral explanation, including data available from literature reviews and the outcome of a scientific advisory group.
Estonian: • Inimravimite komitee võttis arvesse kõiki müügilubade hoidjate kirjalikult ja suuliselt esitatud andmeid, sh avaldatud kirjandusest pärit andmeid ja teadusnõuanderühma töö tulemusi.
English: The product has been used outside its indication, with several trials where risks were observed conducted in a wider patient population.
Estonian: Ravimit on kasutatud ka muudel kui heakskiidetud näidustustel ja mitu riske täheldanud uuringut toimusid suuremas patsiendipopulatsioonis.
English: Antifibrinolytics (e.g. aprotinin, aminocaproic acid and tranexamic acid), are a class of haemostatic agents used to prevent excessive blood loss.
Estonian: Antifibrinolüütikumid (nt aprotiniin, aminokaproonhape ja traneksaamhape) on hemostaatilise toimega ainete klass, mida kasutatakse liigse verekaotuse ennetamiseks.
English: This is important to take into consideration when treating patients with known pre-existing impairment and in patients concomitantly treated with drugs that may affect renal function.
Estonian: Seda on oluline arvestada olemasoleva kahjustusega patsientide ravimisel ja ka nende patsientide korral, kes võtavad samal ajal neerutalitlust häirida võivaid ravimeid.
English: Other notable safety concerns include the identified risk for transient renal impairment, which is a well characterised unfavourable effect of treatment with aprotinin.
Estonian: Teised märkimisväärsed ohutusprobleemid on näiteks ajutise neerukahjustuse tuvastatud risk, mis on aprotiniinravi teadaolev kõrvalnäht.
English: The preliminary results of a randomised controlled clinical trial, the ‘Blood conservation using antifibrinolytics: a randomised trial in a cardiac surgery population' (BART) study, had shown that although the use of aprotinin was associated with less serious bleeding than either of the comparator drugs, an increase in 30 day all-cause mortality had been observed among patients receiving aprotinin compared to patients taking other medicines.
Estonian: Randomiseeritud ja kontrollitud kliinilise uuringu Blood conservation using antifibrinolytics: a randomised trial in a cardiac surgery population (BART) esmased tulemused näitasid, et kuigi aprotiniini seostati kergema verejooksuga kui kummagi võrdlusravimi korral, täheldati aprotiniini kasutanud patsientidel teisi ravimeid saanud patsientidega võrreldes 30-päevase üldsuremuse suurenemist.
English: The CHMP considered that a clarification should be included in the wording of the indication to reflect that the product should be used in patients undergoing CPB in the course of ‘isolated CABG' surgery, as efficacy and safety of aprotinin in more extensive surgery has not been sufficiently characterised.
Estonian: Inimravimite komitee leidis, et näidustuse sõnastusse tuleb lisada selgitus, et ravimit tohib kasutada patsientidel, kellel pärgarteri isoleeritud šunteerimise operatsiooni ajal kasutatakse kehavälist vereringet, sest ulatuslikumate operatsioonide korral ei ole aprotiniini efektiivsust ja ohutust piisavalt iseloomustatud.